+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Hepatitis C Global Clinical Trials Review, H1, 2020

  • ID: 5004144
  • Clinical Trials
  • January 2020
  • Region: Global
  • 2211 pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • AbbVie Inc
  • Bristol-Myers Squibb Co
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • MORE
Hepatitis C Global Clinical Trials Review, H1, 2020

Summary

This clinical trial report, “Hepatitis C Global Clinical Trials Review, H1, 2020" provides an overview of Hepatitis C Clinical trials scenario. This report provides top line data relating to the clinical trials on Hepatitis C. The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. The report also provides prominent drugs for in-progress trials (based on number of ongoing trials). The Clinical Trial Reports are generated using the publisher's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. The clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Scope
  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months
Reasons to buy
  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AbbVie Inc
  • Bristol-Myers Squibb Co
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • MORE
  • Report Guidance
  • Clinical Trials Report Coverage
  • Clinical Trials by Region
  • Clinical Trials and Average Enrollment by Country
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
  • Top Five Countries Contributing to Clinical Trials in Europe
  • Top Countries Contributing to Clinical Trials in North America
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
  • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Hepatitis C to Infectious Disease Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Hepatitis C to Infectious Disease Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
  • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
  • Top Companies Participating in Hepatitis C Therapeutics Clinical Trials
  • Prominent Drugs
  • Latest Clinical Trials News on Hepatitis C
  • Nov 11, 2019: Cocrystal Pharma presents positive data from U.S. phase 2a study of CC-31244 demonstrating ability to identify patients more likely to respond to ultrashort treatment of HCV
  • Nov 08, 2019: Gilead announces new data from viral hepatitis research programs at The Liver Meeting 2019
  • Oct 30, 2019: Cocrystal Pharma announces new data on CC-31244 and abstract acceptance for poster presentation at the AASLD 2019 Liver Meeting
  • Clinical Trial Profile Snapshots
  • Appendix
  • Abbreviations
  • Definitions
  • Research Methodology
  • Secondary Research
  • About the Publisher
  • Contact Us
  • Source
List of Tables
  • Hepatitis C Therapeutics, Global, Clinical Trials by Region, 2020*
  • Hepatitis C Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2020*
  • Hepatitis C Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2020*
  • Hepatitis C Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2020*
  • Hepatitis C Therapeutics Clinical Trials, Europe, Top Five Countries, 2020*
  • Hepatitis C Therapeutics Clinical Trials, North America, Top Countries, 2020*
  • Hepatitis C Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2020*
  • Hepatitis C Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2020*
  • Proportion of Hepatitis C to Infectious Disease Clinical Trials, G7 Countries (%), 2020*
  • Hepatitis C Therapeutics, G7 Countries, Clinical Trials by Phase, 2020*
  • Hepatitis C Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2020*
  • Proportion of Hepatitis C to Infectious Disease Clinical Trials, E7 Countries (%), 2020*
  • Hepatitis C Therapeutics, E7 Countries, Clinical Trials by Phase, 2020*
  • Hepatitis C Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2020*
  • Hepatitis C Therapeutics, Global, Clinical Trials by Phase, 2020*
  • Hepatitis C Therapeutics, Global, Clinical Trials In Progress by Phase 2020*
  • Hepatitis C Therapeutics, Global, Clinical Trials by Trial Status, 2020*
  • Hepatitis C Therapeutics Clinical Trials, Global, by End Point Status, 2020*
  • Hepatitis C Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018
  • Hepatitis C Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2020*
  • Hepatitis C Therapeutics Clinical Trials, Global, Key Sponsors, 2020*
  • Hepatitis C Therapeutics Clinical Trials, Global, Top Companies by Phase, 2020*
  • Hepatitis C Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2020*
List of Figures
  • Hepatitis C Therapeutics, Global, Clinical Trials by Region (%), 2020*
  • Hepatitis C Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2020*
  • Hepatitis C Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2020*
  • Hepatitis C Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2020*
  • Hepatitis C Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2020*
  • Hepatitis C Therapeutics Clinical Trials, North America, Top Countries (%), 2020*
  • Hepatitis C Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2020*
  • Hepatitis C Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2020*
  • Proportion of Hepatitis C to Infectious Disease Clinical Trials, G7 Countries (%), 2020*
  • Hepatitis C Therapeutics, G7 Countries, Clinical Trials by Phase, 2020*
  • Hepatitis C Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2020*
  • Proportion of Hepatitis C to Infectious Disease Clinical Trials, E7 Countries (%), 2020*
  • Hepatitis C Therapeutics, E7 Countries, Clinical Trials by Phase, 2020*
  • Hepatitis C Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2020*
  • Hepatitis C Therapeutics, Global, Clinical Trials by Phase (%), 2020*
  • Hepatitis C Therapeutics, Global, Clinical Trials In Progress by Phase, 2020*
  • Hepatitis C Therapeutics, Global, Clinical Trials by Trial Status, 2020*
  • Hepatitis C Therapeutics Clinical Trials, Global, by End Point Status, 2020*
  • Hepatitis C Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018
  • Hepatitis C Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2020*
  • Hepatitis C Therapeutics Clinical Trials, Global, Key Sponsors, 2020*
  • Hepatitis C Therapeutics Clinical Trials, Global, Top Companies by Phase, 2020*
  • Hepatitis C Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2020*
  • Report Methodology
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Merck & Co Inc
  • Gilead Sciences Inc
  • F. Hoffmann-La Roche Ltd
  • AbbVie Inc
  • Johnson & Johnson
  • Bristol-Myers Squibb Co
  • Vertex Pharmaceuticals Inc
  • C. H. Boehringer Sohn AG & Co KG
  • GlaxoSmithKline Plc
  • Novartis AG
Note: Product cover images may vary from those shown
Adroll
adroll